IntraMed - Artículos - Cáncer de mama
Una revisión y puesta al día | 29 ABR 14
Cáncer de mama
Esta revisión intenta brindar un panorama sobre el diagnóstico, tratamiento y seguimiento de las pacientes con cáncer de mama.
Autor: Dr. Matsen CB, Neumayer LA JAMA Surg 2013; 148(10): 971-979
INDICE:  1.  | 2. Referencias
Referencias

1. American Cancer Society. Breast cancer: facts & figures 2011-2012.
 http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/
document/acspc-030975.pdf
. Accessed October 11, 2012.
2. Freedman  AN, Seminara  D, Gail  MH,  et al.  Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97(10):715-723.
3. Gail  MH, Brinton  LA, Byar  DP,  et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886.
4. Matsuno  RK, Costantino  JP, Ziegler  RG,  et al.  Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103(12):951-961.
5. Gail  MH, Costantino  JP, Pee  D,  et al.  Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99(23):1782-1792.
6. Banegas  MP, Gail  MH, LaCroix  A,  et al.  Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat. 2012;132(1):347-353.
7. Vogel  VG, Costantino  JP, Wickerham  DL,  et al; National Surgical Adjuvant Breast and Bowel Project (NSABP).  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes:
the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
8. Vogel  VG, Costantino  JP, Wickerham  DL,  et al; National Surgical Adjuvant Breast and Bowel Project.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial:
preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706.
9. Wickerham  DL.  Breast cancer chemoprevention: progress and controversy. Surg Oncol Clin North Am. 2010;19(3):463-473.
10. Oppong  BA, King  TA.  Recommendations for women with lobular carcinoma in situ (LCIS). Oncology (Williston Park). 2011;25(11):1051-1056, 1058.
11. Anderson  BO, Calhoun  KE, Rosen  EL.  Evolving concepts in the management of lobular neoplasia. J Natl Compr Canc Netw. 2006;4(5):511-522.
12. Fisher  B, Costantino  JP, Wickerham  DL,  et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652-1662.
13. Njiaju  UO, Olopade  OI.  Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J. 2012;18(5):436-442.
14. Shannon  KM, Chittenden  A.  Genetic testing by cancer site: breast. Cancer J. 2012;18(4):310-319.
15. Bevers  TB, Anderson  BO, Bonaccio  E,  et al.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw. 2009;7(10):1060-1096.
16. Brown  P.  Risk assessment: controversies and management of moderate- to high-risk individuals. Breast J. 2005;11(suppl 1):S11-S19.
17. Miki  Y, Swensen  J, Shattuck-Eidens  D,  et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
18. Wooster  R, Neuhausen  SL, Mangion  J,  et al.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-2090.
19. Petrucelli  N, Daly  MB, Feldman  GL.  Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245-259.
20. Smith  KL, Isaacs  C.  BRCA mutation testing in determining breast cancer therapy. Cancer J. 2011;17(6):492-499.
21. Nyström  L, Andersson  I, Bjurstam  N, Frisell  J, Nordenskjöld  B, Rutqvist  LE.  Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909-919.
22. Alexander  FE, Anderson  TJ, Brown  HK,  et al.  14 Years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 1999;353(9168):1903-1908.
23. Berry  DA, Cronin  KA, Plevritis  SK,  et al; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators.  Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784-1792.
24. American Cancer Society. American Cancer Society guidelines for the early detection of cancer.
http://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/
american-cancer-society-guidelines-for-the-early-detection-of-cancer
. Accessed October 11, 2012.
25. US Preventive Services Task Force. Screening for breast cancer. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm. Accessed October 11, 2012.
26. Nelson  HD, Tyne  K, Naik  A, Bougatsos  C, Chan  BK, Humphrey  L.  Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med.2009;151(10):727-737, W237-W242.
27. Howard  DH, Adams  EK.  Mammography rates after the 2009 US Preventive Services Task Force breast cancer screening recommendation. Prev Med. 2012;55(5):485-487.
28. Kerlikowske  K, Hubbard  RA, Miglioretti  DL,  et al; Breast Cancer Surveillance Consortium.  Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155(8):493-502.
29. Nelson  HD, Zakher  B, Cantor  A,  et al.  Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635-648.
30. de Koning  HJ, Boer  R, Warmerdam  PG, Beemsterboer  PM, van der Maas  PJ.  Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst. 1995;87(16):1217-1223.
31. Hofvind  S, Geller  BM, Skelly  J, Vacek  PM.  Sensitivity and specificity of mammographic screening as practiced in Vermont and Norway. Br J Radiol. 2012;85(1020):e1226-e1232
32. Gøtzsche  PC, Nielsen  M.  Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;(1):CD001877. doi:10.1002/14651858.CD001877.pub4.
33. Hendrick  RE, Helvie  MA.  United States Preventive Services Task Force screening mammography recommendations: science ignored. AJR Am J Roentgenol. 2011;196(2):W112-W116.
34. Mandelblatt  JS, Cronin  KA, Bailey  S,  et al; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network.  Effects of mammography screening under different screening schedules:
model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-747.
35. Centers for Disease Control and Prevention (CDC).  Cancer screening—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(3):41-45
36. Hoerger  TJ, Ekwueme  DU, Miller  JW,  et al.  Estimated effects of the National Breast and Cervical Cancer Early Detection Program on breast cancer mortality. Am J Prev Med. 2011;40(4):397-404.
37. Pisano  ED, Gatsonis  C, Hendrick  E,  et al; Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group.  Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353(17):1773-1783.
38. Granader  EJ, Dwamena  B, Carlos  RC.  MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol. 2008;15(12):1590-1595.
39. Heller  SL, Moy  L.  Imaging features and management of high-risk lesions on contrast-enhanced dynamic breast MRI. AJR Am J Roentgenol. 2012;198(2):249-255.
40. Morrow  M, Waters  J, Morris  E.  MRI for breast cancer screening, diagnosis, and treatment. Lancet. 2011;378(9805):1804-1811.
41. Moon  H-G, Han  W, Ahn  SK,  et al.  Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg.2013;257(1):133-137.
42. Turnbull  L, Brown  S, Harvey  I,  et al.  Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010;375(9714):563-571.
43. Gennaro  G, Hendrick  RE, Ruppel  P,  et al.  Performance comparison of single-view digital breast tomosynthesis plus single-view digital mammography with two-view digital mammography. Eur Radiol. 2012;23(3):664-672.
44. Shin  HJ, Kim  HH, Cha  JH, Park  JH, Lee  KE, Kim  JH.  Automated ultrasound of the breast for diagnosis: interobserver agreement on lesion detection and characterization. AJR Am J Roentgenol. 2011;197(3):747-754.
45. Lewis  JL, Lee  DY, Tartter  PI.  The significance of lobular carcinoma in situ and atypical lobular hyperplasia of the breast. Ann Surg Oncol. 2012;19(13):4124-4128.
46. Ingegnoli  A, d’Aloia  C, Frattaruolo  A,  et al.  Flat epithelial atypia and atypical ductal hyperplasia: carcinoma underestimation rate. Breast J. 2010;16(1):55-59.
47. Kohr  JR, Eby  PR, Allison  KH,  et al.  Risk of upgrade of atypical ductal hyperplasia after stereotactic breast biopsy: effects of number of foci and complete removal of calcifications. Radiology. 2010;255(3):723-730.
48. Sinn  H-P, Elsawaf  Z, Helmchen  B, Aulmann  S.  Early breast cancer precursor lesions: lessons learned from molecular and clinical studies. Breast Care (Basel). 2010;5(4):218-226.
49. Dillon  MF, McDermott  EW, Hill  AD, O’Doherty  A, O’Higgins  N, Quinn  CM.  Predictive value of breast lesions of “uncertain malignant potential” and “suspicious for malignancy” determined by needle core biopsy. Ann Surg Oncol. 2007;14(2):704-711.
50. Fisher  B, Redmond  C, Brown  A,  et al.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol. 1983;1(4):227-241.
51. Robertson  FM, Bondy  M, Yang  W,  et al.  Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351-375.
52. Mendez  A, Cabanillas  F, Echenique  M, Malekshamran  K, Perez  I, Ramos  E.  Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB). Ann Oncol. 2004;15(3):450-454.
53. Silverstein  MJ, Lagios  MD.  Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr. 2010;2010(41):193-196.
54. Diab  SG, Clark  GM, Osborne  CK, Libby  A, Allred  DC, Elledge  RM.  Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999;17(5):1442-1448.
55. Rakha  EA, Lee  AHS, Evans  AJ,  et al.  Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99-104.
56. Chen  C-Y, Sun  L-M, Anderson  BO.  Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer. 2006;107(7):1448-1458.
57. Yim  JH, Wick  MR, Philpott  GW, Norton  JA, Doherty  GM.  Underlying pathology in mammary Paget’s disease. Ann Surg Oncol. 1997;4(4):287-292.
58. Khosravi-Shahi  P.  Management of non-metastatic phyllodes tumors of the breast: review of the literature. Surg Oncol. 2011;20(4):e143-e148.
59. Kelly  CM, Bernard  PS, Krishnamurthy  S,  et al.  Agreement in risk prediction between the 21-gene recurrence score assay (OncoType DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor–positive breast cancer.
Oncologist. 2012;17(4):492-498.
60. Oakman  C, Santarpia  L, Di Leo  A.  Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 2010;7(12):725-732.
61. Albain  KS, Barlow  WE, Shak  S,  et al; Breast Cancer Intergroup of North America.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
62. Albain  KS, Paik  S, van’t Veer  L.  Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast. 2009;18(suppl 3):S141-S145.
63. Slodkowska  EA, Ross  JS.  MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009;9(5):417-422.
64. Bastien  RR, Rodríguez-Lescure  A, Ebbert  MT,  et al.  PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012;5(1):44. doi: 10.1186/1755-8794-5-44.
65. Chia  SK, Bramwell  VH, Tu  D,  et al.  A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18(16):4465-4472.
66. Cheang  MCU, Voduc  KD, Tu  D,  et al.  Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res. 2012;18(8):2402-2412.
67. Kim  C, Paik  S.  Gene-expression–based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7(6):340-347.
68. Virnig  BA, Tuttle  TM, Shamliyan  T, Kane  RL.  Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170-178.
69. Halsted  WS.  The results of operation for the cure of cancer of the breast performed at John Hopkins Hospital from June 1889 to January 1894. Ann Surg. 1894;20(5):497-555.
70. McGuire  KP, Santillan  AA, Kaur  P,  et al.  Are mastectomies on the rise? a 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol. 2009;16(10):2682-2690.
71. Fisher  B, Jeong  J-H, Anderson  S, Bryant  J, Fisher  ER, Wolmark  N.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567-575.
72. Fisher  B, Anderson  S, Bryant  J,  et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.
73. Wijayanayagam  A, Kumar  AS, Foster  RD, Esserman  LJ.  Optimizing the total skin-sparing mastectomy. Arch Surg. 2008;143(1):38-45.
74. Murthy  V, Chamberlain  RS.  Defining a place for nipple-sparing mastectomy in modern breast care: an evidence based review [published online January 29, 2012]. Breast J. doi:10.1111/j.1524-4741.2011.01220.x.
75. Jensen  JA, Orringer  JS, Giuliano  AE.  Nipple-sparing mastectomy in 99 patients with a mean follow-up of 5 years. Ann Surg Oncol. 2011;18(6):1665-1670.
76. Garcia-Etienne  CA, Cody  HS  III, Disa  JJ, Cordeiro  P, Sacchini  V.  Nipple-sparing mastectomy: initial experience at the Memorial Sloan-Kettering Cancer Center and a comprehensive review of literature. Breast J. 2009;15(4):440-449.
77. Babiera  G, Simmons  R.  Nipple-areolar complex-sparing mastectomy: feasibility, patient selection, and technique. Ann Surg Oncol. 2010;17(suppl 3):245-248.
78. Bedrosian  I, Hu  C-Y, Chang  GJ.  Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401-409.
79. Brewster  AM, Parker  PA.  Current knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer. Oncologist. 2011;16(7):935-941.
80. Morton  DL, Wen  DR, Wong  JH,  et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127(4):392-399.
81. Giuliano  AE, Kirgan  DM, Guenther  JM, Morton  DL.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.
82. Giuliano  AE, Dale  PS, Turner  RR, Morton  DL, Evans  SW, Krasne  DL.  Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222(3):394-401.
83. Krag  DN, Anderson  SJ, Julian  TB,  et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Lancet Oncol. 2010;11(10):927-933.
84. Van Zee  KJ, Manasseh  D-ME, Bevilacqua  JLB,  et al.  A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140-1151.
85. Gur  AS, Unal  B, Johnson  R,  et al.  Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208(2):229-235.
86. Erb  KM, Julian  TB.  Completion of axillary dissection for a positive sentinel node: necessary or not? Curr Oncol Rep. 2009;11(1):15-20.
87. Deutsch  M, Land  S, Begovic  M, Sharif  S.  The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus
total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys. 2008;70(4):1020-1024.
88. Giuliano  AE, Hunt  KK, Ballman  KV,  et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569-575.
89. Giuliano  AE, McCall  L, Beitsch  P,  et al.  Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases:
the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426-433.
90. Gainer  SM, Hunt  KK, Beitsch  P, Caudle  AS, Mittendorf  EA, Lucci  A.  Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol. 2012;19(10):3152-3158.
91. Barry  JM, Weber  WP, Sacchini  V.  The evolving role of axillary lymph node dissection in the modern era of breast cancer management. Surg Oncol. 2012;21(2):143-145.
92. Lambert  K, Patani  N, Mokbel  K.  Ductal carcinoma in situ: recent advances and future prospects. Int J Surg Oncol. 2012;2012:347385. doi:10.1155/2012/347385.
93. Mamounas  EP, Brown  A, Anderson  S,  et al.  Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 [published correction appears in J Clin Oncol. 2005;23(21):4808]. J Clin Oncol. 2005;23(12):2694-2702.
94. Newman  EA, Sabel  MS, Nees  AV,  et al.  Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14(10):2946-2952.
95. Edge  SB, Byrd  DR, Compton  CC, eds. AJCC Cancer Staging Manual.7th ed. New York, NY: Springer; 2010.
96. Martin  M, Villar  A, Sole-Calvo  A,  et al; GEICAM Group (Spanish Breast Cancer Research Group), Spain.  Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21)
versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM Group. Ann Oncol. 2003;14(6):833-842.
97. Gianni  L, Norton  L, Wolmark  N, Suter  TM, Bonadonna  G, Hortobagyi  GN.  Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol. 2009;27(28):4798-4808.
98. Paik  S, Taniyama  Y, Geyer  CE  Jr.  Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst. 2008;100(1):2-4.
99. Albini  A, Pennesi  G, Donatelli  F, Cammarota  R, De Flora  S, Noonan  DM.  Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14-25.
100. Sawaya  H, Sebag  IA, Plana  JC,  et al.  Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603.
101. Bowles  EJA, Wellman  R, Feigelson  HS,  et al; Pharmacovigilance Study Team.  Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293-1305.
102. Ginés  J, Sabater  E, Martorell  C, Grau  M, Monroy  M, Casado  MA.  Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol. 2011;13(7):485-498.
103. Bear  HD, Anderson  S, Smith  RE,  et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:
National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
104. Ferguson  T, Wilcken  N, Vagg  R, Ghersi  D, Nowak  AK.  Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2007;(4):CD004421.
105. Kaufmann  M, von Minckwitz  G, Mamounas  EP,  et al.  Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508-1516.
106. Bear  HD, Anderson  S, Brown  A,  et al; National Surgical Adjuvant Breast and Bowel Project Protocol B-27.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-4174.
107. Vilarino-Varela  M, Chin  YS, Makris  A.  Current indications for post-mastectomy radiation. Int Semin Surg Oncol. 2009;6:5. doi: 10.1186/1477-7800-6-5.
108. Smith  BD, Arthur  DW, Buchholz  TA,  et al.  Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74(4):987-1001.
109. Vicini  F, Beitsch  P, Quiet  C,  et al.  Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2011;79(3):808-817.
110. Vaidya  JS, Joseph  DJ, Tobias  JS,  et al.  Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010;376(9735):91-102.
111. Khan  AJ, Arthur  D, Vicini  F,  et al.  Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2012;19(5):1477-1483.
112. Goyal  S, Khan  AJ, Vicini  F,  et al.  Factors associated with optimal cosmetic results at 36 months in patients treated with accelerated partial breast irradiation (APBI) on the American Society of Breast Surgeons (ASBrS) MammoSite Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2009;16(9):2450-2458.
113. McCormick  B.  Hypofractionated whole breast radiation and partial breast radiation for early-stage breast cancers: an update on progress. J Natl Compr Canc Netw. 2012;10(9):1161-1164.
114. Davies  C, Pan  H, Godwin  J,  et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
115. Howell  A, Cuzick  J, Baum  M,  et al; ATAC Trialists’ Group.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
116. Tandon  AK, Clark  GM, Chamness  GC, Ullrich  A, McGuire  WL.  HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120-1128.
117. Carr  JA, Havstad  S, Zarbo  RJ, Divine  G, Mackowiak  P, Velanovich  V.  The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg. 2000;135(12):1469-1474.
118. Romond  EH, Perez  EA, Bryant  J,  et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
119. Paik  S, Kim  C, Wolmark  N.  HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 2008;358(13):1409-1411.
120. Moja  L, Tagliabue  L, Balduzzi  S,  et al.  Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243. doi:10.1002/14651858.CD006243.pub2.
121. Perez  EA, Romond  EH, Suman  VJ,  et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from
NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-3373.
122. Baselga  J, Cortés  J, Kim  S-B,  et al; CLEOPATRA Study Group.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
123. Capelan  M, Pugliano  L, De Azambuja  E,  et al.  Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273-282.
124. Gianni  L, Pienkowski  T, Im  Y-H,  et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere):
a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
125. Untch  M, Loibl  S, Bischoff  J,  et al; German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group.
  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13(2):135-144.
126. Seidman  A, Hudis  C, Pierri  MK,  et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-1221.
127. Chen  J, Long  JB, Hurria  A, Owusu  C, Steingart  RM, Gross  CP.  Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504-2512.
128. Wagner  AD, Thomssen  C, Haerting  J, Unverzagt  S.  Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012;7:CD008941. doi:10.1002/14651858.CD008941.pub2.
129. Khatcheressian  JL, Wolff  AC, Smith  TJ,  et al; American Society of Clinical Oncology.  American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091-5097.

Comentarios

Usted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí
Dr. Jose Guadalupe Vega Villagómez   Hace 1 año
No se ha demostrado que la biopsia por aspiración no produzca vias de diseminación.
Muchas comentarios en inmunogénesis y tratamientos colaterales a la cirugia pero sin cambios significativos en la supervivencia.
Los más...
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2014